John V. Heymach

1. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib
   2017/05/10 by Triparna Sen, Pan Tong, C. Allison Stewart +16 · 29 citations
   Biochemistry, Genetics and Molecular Biology · Medicine · #Biology #Biomarker #Cancer #Cancer research #Cancer therapeutics and mechanisms #Chemotherapy #Cisplatin #In vivo #Internal medicine #Lung Cancer Research Studies #Lung Cancer Treatments and Mutations #Lung cancer #Medicine #Olaparib #Oncology #PARP inhibitor #Pharmacology #Poly ADP ribose polymerase #Polymerase
2. Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS -Mutant Non–Small Cell Lung Cancer
   2024/07/05 by Haniel A. Araújo, Ximo Pechuan-Jorge, Teng Zhou +24 · 1 voice · 6 citations
   Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer Immunotherapy and Biomarkers #Cancer-related Molecular Pathways #Ubiquitin and proteasome pathways
3. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
   2018/01/30 by John V. Heymach, Lada Krilov, Anthony J. Alberg +19 · 1 citation
   Medicine · Biochemistry, Genetics and Molecular Biology · #CAR-T cell therapy research #Cancer Genomics and Diagnostics #Cancer Immunotherapy and Biomarkers